# US 2024/0252689 A1 · Poly-adp ribose (par) tracker optimized split-protein reassembly par detection reagents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252689 A1
- Document ID: US20240252689A1
- Status: Published application
- Kind: A1
- Application number: 18/561,044
- Filed: 2022-05-18
- Published: 2024-08-01
- Earliest claimed: 2021-05-18
- Assignees: Board of Regents, The University of Texas System
- Applicants: The Board of Regents of the University of Texas System
- Inventors: W. Lee KRAUS; Keun Woo RYU; Sridevi CHALLA
- Web page: https://patentgrep.com/patent/US20240252689A1

## CPC

- A61K 49/0047: {Green fluorescent protein [GFP]}
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61K 49/0045: {the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- C12N 9/1077: {Pentosyltransferases (2.4.2)}
- C12Q 1/48: involving transferase
- C12Q 1/66: involving luciferase
- C12Y 204/0203: NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
- G01N 2333/91142: Pentosyltransferases (2.4.2)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are split reporter systems for detecting poly-ADP ribose polymerase activity in living systems. In some aspects, the split reporter systems comprise a first fusion protein comprising a first fragment of a reporter protein functionally linked to a first poly-ADP ribose binding moiety; and a second fusion protein comprising a second fragment of the reporter protein functionally linked to a second poly-ADP ribose binding moiety wherein the first and second fragments of the reporter protein are each non-functional and capable of recombining, optionally in the presence of a substrate, to form a functional reporter protein capable of producing a detectable signal. Also provided are methods of use thereof.

## Claims

### Claim 1

A split reporter system for detecting poly-ADP ribose polymerase (PARP) activity comprising:
(a) a first fusion protein comprising a first fragment of a reporter protein functionally linked to a first poly-ADP ribose binding moiety; and
(b) a second fusion protein comprising a second fragment of the reporter protein functionally linked to a second poly-ADP ribose binding moiety;
wherein the first and second fragments of the reporter protein are each non-functional and capable of recombining, optionally in the presence of a substrate, to form a functional reporter protein capable of producing a detectable signal.

### Claim 2 (depends on 1)

The split reporter system of claim 1, wherein the reporter protein comprises a fluorescent or a luminescent protein.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The split reporter system of claim 2, wherein the reporter protein comprises a luciferase.

### Claim at position 5

5-9. (canceled)

### Claim 10

A split reporter system for detecting poly-ADP ribose polymerase (PARP) activity comprising:
(a) a first fusion protein comprising a first monomer of a dimerization-dependent reporter system functionally linked to a first poly-ADP ribose binding moiety; and
(b) a second fusion protein comprising a second monomer of the dimerization dependent reporter system functionally linked to a second poly-ADP ribose binding moiety;
wherein the first and second monomers of the dimerization dependent reporter system are capable of combining to form a heterodimer of the dimerization-dependent reporter system, the heterodimer capable of emitting a detectable light signal.

### Claim 11 (depends on 10)

The split reporter system of claim 10, wherein the dimerization dependent reporter system comprises a dimerization-dependent GFP, a dimerization-dependent YFP, or a dimerization dependent RFP.

### Claim 12

(canceled)

### Claim 13 (depends on 10)

The split reporter system of claim 10, wherein the first and/or second monomers are operably linked to a second fluorescent protein excited by light emitted from the heterodimer when the heterodimer is excited by electromagnetic radiation.

### Claim 14 (depends on 13)

The split reporter system of claim 13, wherein the second fluorescent protein comprises mOrange, cpVenus or GFP.

### Claim 15 (depends on 10)

The split reporter system of claim 10, wherein at least one of the first or second poly-ADP ribose binding moieties comprise a macro domain.

### Claim 16 (depends on 15)

The split reporter system of claim 15, wherein the macro domain comprises a macro domain derived from an ADP ribose glycohydrolase AF1521.

### Claim 17 (depends on 16)

The split reporter system of claim 16, wherein the macro domain comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1.

### Claim 18 (depends on 10)

The split reporter system of claim 10, wherein at least one of the first and second poly-ADP ribose binding moieties comprises a WWE domain.

### Claim 19 (depends on 18)

The split reporter system of claim 18, wherein the WWE domain comprises a WWE domain derived from an RNF146 E3 ligase.

### Claim 20 (depends on 19)

The split reporter system of claim 19, wherein the WWE domain has an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2.

### Claim 21 (depends on 10)

The split reporter system of claim 10, wherein the first and second poly ADP ribose binding moieties lack a PBZ domain having an amino acid sequence comprising SEQ ID NO: 3.

### Claim 22 (depends on 10)

A nucleic acid construct comprising a nucleic acid sequence that encodes for the first and/or second fusion protein of claim 10.

### Claim 23 (depends on 22)

An expression vector comprising at least one nucleic acid construct of claim 22.

### Claim 24 (depends on 23)

A host cell comprising one or more expression vectors of claim 23.

### Claim 25 (depends on 10)

A method of detecting poly-ADP ribose polymerase (PARP) activity in a cell or tissue suspected of having PARP activity, the method comprising:
(a) introducing the first and second fusion proteins of claim 10 into the cell or tissue;
(b) maintaining the cell or tissue for a time and under conditions sufficient for the first and second fusion proteins to bind to one or more poly-ADP ribose (PAR) chains and combine to produce a signal; and
(c) detecting the signal, wherein the signal is proportional to the PARP activity in the system.

### Claim 26 (depends on 10)

A method of assessing the effectiveness of a potential therapeutic comprising (a) introducing the first and second fusion proteins of claim 10 into a cell, tissue or animal, (b) applying the potential therapeutic to the cell or tissue, (c) maintaining the cell or tissue for a time and under conditions sufficient for the first and second fusion proteins to bind to one or more poly-ADP ribose (PAR) chains and combine to produce a signal; and (d) detecting the signal, wherein the signal is indicative of the efficacy of the potential therapeutic.

### Claim at position 23

27-36. (canceled)

### Claim 37 (depends on 10)

A kit comprising one or more of the first or second fusion proteins of claim 10 and at least one container.
